Drug Trial Radar · NCT04410978
Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)
Last checked: Nov 20, 2026Latest source record: Jul 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
974
Actual
Start
Jun 30, 2020
Primary completion
Jul 15, 2024
Study completion Jul 15, 2024
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jun 1, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: To assess efficacy of daily SAR442168 compared to a daily dose of 14 mg teriflunomide (Aubagio) measured by annualized adjudicated relapse rate (ARR) in participants with relapsing forms of MS Secondary Objective: To assess efficacy of SAR442168 compared to teriflunomide (Aubagio) on disability progression, MRI lesions, cognitive performance and quality of life To evaluate the safety and tolerability of daily SAR442168 To evaluate population pharmacokinetics (PK) of SAR442168 and relevant metabolites and its relationship to efficacy and safety To evaluate pharmacodynamics (PD) of SAR442168
Conditions
- Relapsing Multiple Sclerosis
Interventions
TolebrutinibDrug
Pharmaceutical form: Tablet Route of administration: Oral
TeriflunomideDrug
Pharmaceutical form: Tablet Route of administration: Oral
Placebo to match TolebrutinibDrug
Pharmaceutical form: Tablet Route of administration: Oral
Placebo to match TeriflunomideDrug
Pharmaceutical form: Tablet Route of administration: Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Relapse Rate (ARR) as Assessed by Confirmed Protocol-defined Adjudicated RelapsesTime frame: Baseline (Day 1) to approximately 48 months
Locations
179 sites in 24 countries. Site status is shown where the registry gives one.
University of Alabama MS Center-Site Number:8400013
Birmingham, Alabama
University of San Francisco, Sandler Neurosciences Center-Site Number:8400137
San Francisco, California
University of Colorado-Site Number:8400012
Aurora, Colorado
Georgetown University Medical Center-Site Number:8400119
Washington D.C., District of Columbia
Beth Israel Deaconess Medical Center-Site Number:8400064
Fort Myers, Florida
Axiom Clinical Research of Florida-Site Number:8400001
Tampa, Florida
University of South Florida-Site Number:8400006
Tampa, Florida
Meridian Clinical Research-Site Number:8400003
Savannah, Georgia
Consultants In Neurology-Site Number:8400011
Northbrook, Illinois
Tufts Medical Center-Site Number:8400072
Boston, Massachusetts
Michigan Institute For Neurological Disorders-Site Number:8400058
Farmington Hills, Michigan
The Memorial Hospital-Site Number:8400033
Owosso, Michigan
Sharlin Health & Neurology-Site Number:8400093
Ozark, Missouri
Missouri Baptist Medical Center-Site Number:8400019
St Louis, Missouri
Meridian Clinical Research, LLC-Site Number:8400005
Raleigh, North Carolina
Wake Forest University Baptist Medical Center-Site Number:8400116
Winston-Salem, North Carolina
The Ohio State University Wexner Medical Center-Site Number:8400150
Columbus, Ohio
Optimed Research, LTD-Site Number:8400147
Columbus, Ohio
Columbus Neuroscience-Site Number:8400010
Westerville, Ohio
Oklahoma Medical Research Foundation-Site Number:8400018
Oklahoma City, Oklahoma
Providence Multiple Sclerosis Center-Site Number:8400020
Portland, Oregon
University of Texas Southwestern Medical Center-Site Number:8400077
Dallas, Texas
Multiple Sclerosis Center, Swedish Neuroscience Institute-Site Number:8400121
Seattle, Washington
Investigational Site Number :0400004
Linz, Austria
Investigational Site Number :1120005
Vitebsk, Belarus
Investigational Site Number :1120004
Vitebsk, Belarus
Investigational Site Number :1000002
Pleven, Bulgaria
Investigational Site Number :1000005
Plovdiv, Bulgaria
Investigational Site Number :1000004
Sofia, Bulgaria
Investigational Site Number :1000008
Sofia, Bulgaria
Investigational Site Number :1000001
Sofia, Bulgaria
Investigational Site Number :1000006
Sofia, Bulgaria
Investigational Site Number :1000009
Sofia, Bulgaria
Investigational Site Number :1240016
Vancouver, British Columbia, Canada
Investigational Site Number :1240003
Ottawa, Ontario, Canada
Investigational Site Number :1240013
Toronto, Ontario, Canada
Investigational Site Number :1240006
Gatineau, Quebec, Canada
Investigational Site Number :1560022
Baotou, China
Investigational Site Number :1560006
Beijing, China
Investigational Site Number :1560010
Beijing, China
Showing 40 of 179 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.